KR910011247A - 신규한 단일층 경피 약제 투여시스템 - Google Patents

신규한 단일층 경피 약제 투여시스템 Download PDF

Info

Publication number
KR910011247A
KR910011247A KR1019900019842A KR900019842A KR910011247A KR 910011247 A KR910011247 A KR 910011247A KR 1019900019842 A KR1019900019842 A KR 1019900019842A KR 900019842 A KR900019842 A KR 900019842A KR 910011247 A KR910011247 A KR 910011247A
Authority
KR
South Korea
Prior art keywords
patch
mammal
matrix
albuterol
skin
Prior art date
Application number
KR1019900019842A
Other languages
English (en)
Inventor
파라디에 바아람
다타트레이 고크해일 라제브
Original Assignee
폴 디. 매튜카이티스
지.디.썰 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 디. 매튜카이티스, 지.디.썰 앤드 캄파니 filed Critical 폴 디. 매튜카이티스
Publication of KR910011247A publication Critical patent/KR910011247A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

내용 없음

Description

신규한 단일층 경피 약제 투여시스템
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 각종 보조제가 알부테롤의 흐름에 어떻게 영향을 끼치는가를 나타내는, 시간에 대한 일부테롤의 전달을 나타내는 도면이다.

Claims (13)

  1. a.소정두께와 면적의 엘라스토머 매트릭스;b.상기한 매트릭스에 두루 분산된 활성약제 성분; 및 c.상기한 매트릭스에 두루 분산된 확산증강제로 이루어지는, 액제를 경피 투여하기 위한 비적층 단일층 첩제.
  2. 제1항에 있어서, a.글리세롤과 같은 가소제;b.n-헥산올과 같은 가용화제; 및 c.상기한 엘라스토머 매트릭스용 경화 촉매로 더 이루어지는 것을 특징으로 하는 첩제.
  3. 제1항에 있어서, 상기한 확산 증강제가 n-도데칸올과 같은 직쇄상 탄화수소 알코올인 것을 특징으로 하는 첩제.
  4. 제1항에 있어서, 상기한 활성 약제 성분이 β2아드레날린성 수용체 길항체, 기관지 확장제 또는 알부테롤인 것을 특징으로 하는 첩제.
  5. a.소정 두께와 면적의 실리콘 엘라스토머 매트릭스;b.약리학적으로 충분한 양의 알부테롤; 및 c.상기한 매트릭스에 두루 분산된, 상기한 알부테롤용 확산 증강제로서의 n-도데칸올로 이루어지는, 약제를 경피 투여하기 위한 비적층 단일층 첩제.
  6. 제5항에 있어서, 상기한 엘라스토머 매트릭스가 약45내지 약95%, w/w의 양으로 존재하는 것을 특징으로 하는 첩제.
  7. 제5항에 있어서, 상기한 알부테롤이 약2내지 30%, w/w의 양으로 존재하는 것을 특징으로 하는 첩제.
  8. 제5항에 있어서, 상기한n-도데칸올이 약3 내지 약30%, w/w의 양으로 존재하는 것을 특징으로 하는 첩제.
  9. 제5항에 있어서, 상기한 활성 약제성분을 1일 첩제 cm2당 약0.2 내지 약 2mg의 방출속도로 공급할 수 있는 것을 특징으로 하는 첩제.
  10. 포유동물의 피부 또는 점막 지역에 제1항의 경피 투여 첩제를 투여하는 단계로 이루어지는 것을 특징으로 하는, 교감 신경 약제를 그것을 필요로하는 포유동물에 투여하는 방법.
  11. 포유동물의 피부 또는 점막 지역에 제1항의 첩제를 가하는 단계로 이루어지는 것을 특징으로 하는, 포유동물의 기관지 협착을 치료하는 방법.
  12. 포유동물의 피부 또는 점막 지역에 제1항의 첩제를 가하는 단계로 이루어지는 것을 특징으로 하는, 임신한 포유동물의 조기 자궁 수축을 지연시키는 방법.
  13. 포유동물의 피부 또는 점막 지역에 제1항의 첩제를 가하는 단계로 이루어지는 것을 특징으로 하는, 포유동물의 담마진을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900019842A 1989-12-04 1990-12-04 신규한 단일층 경피 약제 투여시스템 KR910011247A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42576689A 1989-12-04 1989-12-04
US07425766 1989-12-04

Publications (1)

Publication Number Publication Date
KR910011247A true KR910011247A (ko) 1991-08-07

Family

ID=23687946

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900019842A KR910011247A (ko) 1989-12-04 1990-12-04 신규한 단일층 경피 약제 투여시스템

Country Status (11)

Country Link
US (2) US5164189A (ko)
EP (1) EP0431519B1 (ko)
JP (1) JPH07133230A (ko)
KR (1) KR910011247A (ko)
AT (1) ATE107176T1 (ko)
CA (1) CA2031376A1 (ko)
DE (1) DE69009946T2 (ko)
DK (1) DK0431519T3 (ko)
ES (1) ES2055280T3 (ko)
IE (1) IE66203B1 (ko)
PT (1) PT96059B (ko)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5549924A (en) * 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
CA2247953A1 (en) * 1996-01-29 1997-07-31 E. Charles Pesterfield Jr. Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9719076D0 (en) * 1997-09-09 1997-11-12 Movevirgo Limited A material for producing a medical dressing and a medical dressing produced using the material
CN100357143C (zh) * 1998-01-20 2007-12-26 易通公司 起步发动机扭矩限制
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
KR100369779B1 (ko) * 1999-07-12 2003-01-29 주식회사 엘지생명과학 교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US20070218087A1 (en) * 2001-12-07 2007-09-20 Norbert Hoenzelaer Method of controlled release of vanillin for nasal and/or pulmonary uptake
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7388076B2 (en) * 2002-07-16 2008-06-17 University Of South Florida Human immunosuppressive protein
SI1534286T1 (sl) 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
ATE432697T1 (de) 2002-11-18 2009-06-15 Yaupon Therapeutics Inc Analgetische verwendung von (s)-norketamin
WO2004075075A1 (en) * 2003-01-21 2004-09-02 Alza Corporation A computational model for transdermal drug delivery
US20060246104A1 (en) * 2003-04-16 2006-11-02 Massia Stephen P Stable rgd peptidomimetic composition
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8168600B2 (en) * 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5386180B2 (ja) 2006-02-28 2014-01-15 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 真皮細胞のコンパクト凝集のための方法
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
CA2673125C (en) 2006-10-19 2015-04-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DK2078026T3 (da) 2006-11-21 2012-04-30 Rigel Pharmaceuticals Inc Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
CA2835910C (en) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Improved vitamin d content uniformity in pharmaceutical dosage forms
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
WO2009027850A2 (en) * 2007-06-06 2009-03-05 Multi-Tech Specialty Chemicals Co., Ltd. Process for the preparation of xanthophyll crystals
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
RU2509766C2 (ru) 2008-08-22 2014-03-20 Санофи-Авентис [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1н-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
CA2746810C (en) 2008-12-30 2017-03-14 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
CA2749217C (en) 2009-01-23 2017-03-21 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8236862B2 (en) * 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
CA2766643C (en) 2009-07-08 2017-01-03 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
US20110034415A1 (en) * 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
WO2011053468A1 (en) 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
KR20120112600A (ko) 2009-12-23 2012-10-11 사노피 ［４［４?（５?아미노메틸?２?플루오로?페닐）?피페리딘?１?일］?（１ｈ?피롤로?피리딘?일）?메탄온들 및 이들의 합성
RS53456B (en) 2009-12-23 2014-12-31 Sanofi [4 [4- (5-AMINOMETHYL-2-FLUOR-PHENYL) -PIPERIDIN-1-IL] - (1H-Pyrrolo-pyridin-IL) -METHANONE AND THEIR SYNTHESIS
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
WO2011133596A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
CN103068390A (zh) 2010-04-20 2013-04-24 寰宇一家健康研究所 包含哒嗪磺酰胺衍生物的化合物、组合物和方法
AU2011242562B2 (en) 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
PT2598500T (pt) 2010-07-28 2021-07-22 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
DK2635299T3 (da) 2010-11-02 2019-10-21 Univ Columbia Fremgangsmåder til behandling af hårtabsforstyrrelser
PT2638021T (pt) 2010-11-13 2019-01-10 Innocrin Pharmaceuticals Inc 1-(6,7-bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1h-1,2,3-triazol-4-il)propan-1-ol como inibidor de cyp17 para o tratamento de doenças dependentes de andrógeno, doenças tais como o cancro da próstata
BR112013014484A2 (pt) 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
US9169182B2 (en) 2011-02-25 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit FtsZ protein
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
US8748461B2 (en) 2011-06-19 2014-06-10 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
BR102012015199A2 (pt) 2011-06-19 2014-05-13 Viamet Pharmaceuticals Inc Compostos inibidores de metaloenzima
WO2012177728A1 (en) 2011-06-23 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
LT2788343T (lt) 2011-12-11 2018-06-11 Viamet Pharmaceuticals (NC), Inc. Metalo fermentus slopinantys junginiai
DK2804858T3 (da) 2012-01-20 2020-03-16 Mycovia Pharmaceuticals Inc Metalloenzym-inhibitorforbindelser
AU2013235729B2 (en) 2012-03-23 2017-06-01 Baylor University Compositions and methods for inhibition of cathepsins
JP6212107B2 (ja) 2012-03-29 2017-10-11 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 脱毛障害を処置するための方法
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
PL2872126T3 (pl) * 2012-07-16 2018-06-29 Grünenthal GmbH Plaster farmaceutyczny do przezskórnego podawania tapentadolu
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
US20140213555A1 (en) 2013-01-25 2014-07-31 Rigel Pharmaceuticals, Inc. Compounds and method for treating autoimmune diseases
AU2014236947A1 (en) 2013-03-15 2015-09-03 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EP3119415A4 (en) 2014-03-07 2017-11-29 The Arizona Board of Regents on behalf of the University of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
WO2015143184A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3237452A4 (en) 2014-12-23 2018-12-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
MX2017012021A (es) 2015-03-19 2018-01-30 Viamet Pharmaceuticals Inc Compuestos antifungicos y procesos para la fabricacion.
EP3331879B1 (en) 2015-08-04 2020-05-20 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
US10464921B2 (en) 2015-09-18 2019-11-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
CN108779094B (zh) 2015-12-30 2021-11-16 Nqp 1598公司 金属酶抑制剂化合物
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
WO2018002888A1 (en) 2016-06-29 2018-01-04 Halo Life Science, Llc Methods of making low odor choline salts of an organic compound
US10370367B2 (en) 2016-10-26 2019-08-06 Rigel Pharmaceuticals, Inc. IRAK inhibitors and method for making and using
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CA3055292A1 (en) 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP7167069B2 (ja) 2017-06-29 2022-11-08 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害剤ならびに作製および使用のための方法
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
AU2019262142A1 (en) 2018-05-03 2020-11-26 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
MD3788044T2 (ro) 2018-05-03 2023-12-31 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
TW202122393A (zh) 2019-08-30 2021-06-16 美商雷傑製藥公司 吡唑化合物，其配製物以及使用該化合物和/或配製物之方法
JP7443495B2 (ja) 2019-09-06 2024-03-05 ライジェル ファーマシューティカルズ， インコーポレイテッド ヘテロ環式ｒｉｐ１キナーゼ阻害剤
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
MX2022005509A (es) 2019-11-07 2022-10-18 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 heterociclicos.
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4136219A (en) * 1973-02-09 1979-01-23 Odam Norman E Method of applying polyurethane paint to vulcanized rubber
US3935329A (en) * 1973-05-09 1976-01-27 Sheller-Globe Corporation Method of manufacturing new paintable rubber products
US4562075A (en) * 1982-05-20 1985-12-31 Nelson Research & Development Co. Penetration enhancers for transdermal drug delivery of systemic agents
DE2751328A1 (de) * 1976-12-21 1978-06-29 Gen Electric Durch ultraschall verbindbare polyphenylenaether-zusammensetzungen
JPS55139449A (en) * 1979-04-18 1980-10-31 Mitsubishi Gas Chem Co Inc Resin composition
DE3010374A1 (de) * 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
JPS5812304B2 (ja) * 1980-09-16 1983-03-07 旭化成株式会社 芳香族ポリエ−テル樹脂組成物
DE3102253A1 (de) * 1981-01-24 1982-09-02 Basf Ag, 6700 Ludwigshafen Thermoplastische formmasse
AU564528B2 (en) * 1981-02-26 1987-08-13 General Electric Company Polyphenylene ether compositions and process
US4513120A (en) * 1981-03-23 1985-04-23 General Electric Company Polyphenylene ether compositions
JPS57174344A (en) * 1981-04-21 1982-10-27 Mitsubishi Gas Chem Co Inc Impact-resistant polyphenylene ether resin composition
US4360618A (en) * 1981-11-19 1982-11-23 Monsanto Company Low acrylonitrile content styrene-acrylonitrile polymers blended with polyphenylene oxide
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
JPS59204650A (ja) * 1983-05-10 1984-11-20 Japan Synthetic Rubber Co Ltd 熱可塑性樹脂組成物
KR860001431B1 (ko) * 1983-07-01 1986-09-24 닛뽕 고오세이 고무 가부시기 가이샤 열가소성 수지 조성물
NL8303497A (nl) * 1983-10-12 1985-05-01 Gen Electric Voorwerp geheel of gedeeltelijk vervaardigd uit een polymeermengsel en voorzien van een polyurethaanlaklaag of een polyurethaanlijmlaag.
US4578423A (en) * 1983-12-12 1986-03-25 Monsanto Company Polyblends of polyphenylene oxide and styrene-acrylonitrile polymers having broad acrylonitrile compositional distribution
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
DE3347278A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
DE3347277A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
EP0150021A3 (en) * 1984-01-20 1987-07-15 General Electric Company Polyphenylene ether resin compositions having improved melt flow and paintability
US4605670A (en) * 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
DE3409079A1 (de) * 1984-03-13 1985-09-19 Bayer Ag, 5090 Leverkusen Medizinische pflaster
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
EP0177329B1 (en) * 1984-10-05 1992-09-30 Hercon Laboratories Corporation Device for transdermal drug administration
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
DE3685895T2 (de) * 1985-02-25 1992-12-24 Univ Rutgers Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
JPH0747535B2 (ja) * 1985-11-26 1995-05-24 日東電工株式会社 消炎鎮痛用貼付剤
JPS6310716A (ja) * 1986-07-02 1988-01-18 Teijin Ltd β−刺激薬外用剤
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US4820525A (en) * 1987-09-17 1989-04-11 American Home Products Corporation (Del.) Transdermal drug delivery system
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems

Also Published As

Publication number Publication date
ATE107176T1 (de) 1994-07-15
DE69009946T2 (de) 1994-11-03
IE66203B1 (en) 1995-12-13
DK0431519T3 (da) 1994-07-04
US5290561A (en) 1994-03-01
CA2031376A1 (en) 1991-06-05
PT96059A (pt) 1991-09-30
EP0431519B1 (en) 1994-06-15
IE904345A1 (en) 1991-06-05
US5164189A (en) 1992-11-17
EP0431519A1 (en) 1991-06-12
JPH07133230A (ja) 1995-05-23
PT96059B (pt) 1998-07-31
DE69009946D1 (de) 1994-07-21
ES2055280T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
KR910011247A (ko) 신규한 단일층 경피 약제 투여시스템
JP2547726B2 (ja) フェンタニルの皮膚投与およびそのための装置
TW464511B (en) Pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system and preparation method therefor
EP0404807B1 (en) Deprenyl for systemic transdermal administration
AU2008289109B2 (en) High concentration local anesthetic formulations
RU2355387C2 (ru) Трансдермальный гранисетрон
KR890011585A (ko) 경피식 피임약제제형
EP0782861B1 (en) Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation
KR920700602A (ko) 폐경기후의 증후군을 치료하기 위한 경피 흡수 투여 단위 및 투여 방법
WO2002003969A2 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
KR910700044A (ko) 에스트로겐/프로게스틴 경피용량 단위, 시스템 및 방법
AU2018202501B2 (en) Once-a-day replacement transdermal administration of fentanyl
KR20080077998A (ko) 인돌 세로토닌 수용체 효능제를 경피 투여하는 방법 및 그방법에 사용하기 위한 경피 조성물들
US8246981B2 (en) Transdermal method and patch for emesis
DE69730988D1 (de) Neue formulierungen zur transdermale verabreichung von fluoxetinacetat und fluoxetinmaleat
JPH09509948A (ja) タモキシフェン誘導体を含むパッチ形態の経皮系
ATE388687T1 (de) Medikamentöse verabreichung von nikotin in form von kaugummi
JPH0512330B2 (ko)
JPH11505513A (ja) 経皮製剤
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
Gholizadeh et al. Intralesional corticosteroid injection as an effective treatment method for oral lesions: a meta-analysis
Osterholm Noradrenergic mediation of traumatic spinal cord autodestruction
IL147640A (en) Subcutaneous administration of lasofoxifene
US20100158990A1 (en) Transdermal method and patch for corticosteroid administration
JP2933337B2 (ja) 亜飽和経皮投与デバイス

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application